MWNA
AXSM icon

Marshall Wace North America’s Axsome Therapeutics AXSM Stock Holding History

Marshall Wace North America’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-6,919
Closed -$392K – 1452
2021
Q1 		$392K Buy
+6,919
New +$487K ﹤0.01% 1256

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Marshall Wace North America's AXSM Position: Q2 2021 in Review

Marshall Wace North America sold out of Axsome Therapeutics (AXSM) in Q2 2021, closing a stake of 6,919 shares — an estimated $392K sold.

Marshall Wace North America first reported a position in AXSM in Q1 2021 and held it in 1 quarter. The position peaked at $392K in Q1 2021. 176 funds tracked by Wall St. Rank hold AXSM as of Q2 2021.

  • Marshall Wace North America reported no remaining Axsome Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Marshall Wace North America sold 6,919 Axsome Therapeutics shares in Q2 2021, an estimated $392K.
  • Marshall Wace North America first reported a position in Axsome Therapeutics in Q1 2021 and held it in 1 quarter.
  • Marshall Wace North America's Axsome Therapeutics position peaked at $392K in Q1 2021.
  • 176 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.